Orega Biotech
  • Home
  • About us
  • Pipeline
  • News
  • Contact
  • Orphelia pharma
    DISCOVERY.
    Translating cancer science into novel immunotherapies
  • Orphelia pharma
    SCIENCE.
    Reveal unexplored regulators of anticancer immunity

Latest news and report

  • 24 February 2023

    IPH5201 (CD39 mAb): initiation of Phase 2 clinical trial MATISSE


    Read more
  • 23 December 2022

    Happy holidays and Merry Christmas !


    Read more
  • 6 December 2022

    OREGA enters into a License Agreement with Genmab


    Read more
  • 20 October 2022

    37th SITC annual meeting 2022


    Read more
  • 3 June 2022

    PRESS RELEASE – IPH5201 (CD39 mAb) to advance into Phase 2


    Read more
  • 4 April 2022

    AACR annual meeting 2022


    Read more
  • 4 February 2022

    World Cancer Day


    Read more
  • 18 December 2020

    Armand Bensussan awarded the Galien Prize 2020


    Read more
OREGA Biotech - 15 ch. du Saquin, bât. G, F-69130 Ecully
Phone : +33 4 37 49 87 20 – orega@orega-biotech.com